A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

NCT07265674 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Biliary Tract Cancer
Biliary Tract Cancer (BTC)

Interventions

DRUG: Nanvuranlat
OTHER: Physician's Best Choice

Sponsor

J-Pharma Co., Ltd.

Collaborators

[object Object]